Gustavo Adolfo Rivero, MD| Hematology Oncology | MedStar Health
Gustavo Adolfo Rivero

Gustavo Adolfo Rivero, MD
Provider is directly employed by MedStar Health

Specialties: Hematology Oncology

Languages: English

About me

Gustavo Rivero, MD, is a dual fellowship-trained hematology and medical oncologist specializing in the treatment of acute and chronic leukemia. In addition to his clinical work, Dr. Rivero is an Associate Professor at the Department of Medicine at MedStar Georgetown University Hospital. Before joining MedStar Health, Dr. Rivero worked in Oncology services at Baylor St. Luke’s Medical Center and as an Associate Professor  of Hematology and Oncology at Baylor College of Medicine, Houston, Texas.

Dr. Rivero’s areas of clinical expertise include:

  • Acute and chronic myeloid leukemias
  • Acute and chronic lymphoid leukemias
  • Myelodysplastic syndrome
  • Myeloproliferative Neoplasm
  • Clonal hematopoiesis of indetermined potential (CHIP)

Dr. Rivero is committed to providing high-quality, compassionate care. He believes in listening carefully to his patients to engage in a meaningful therapeutic, humanistic, comprehensive approach to treating leukemia. As part of the multidisciplinary team, he works closely with a team of other medical oncologists, surgeons, radiation oncologists, nurses, and patient advocates.

Dr. Rivero received his medical degree at Francisco de Miranda University in Santa Ana de Coro, Venezuela, and completed his Internal Medicine residency at Cook County Hospital, Chicago, Illinois. He completed a dual fellowship in Hematology and Medical Oncology at the National Institute of Health, Bethesda, Maryland.

Dr. Rivero’s research focus:

Dr. Rivero’s research focuses on studying and designing clinical trials to improve the outcome of Leukemias (a bone marrow malignancy disorder that compromises the normal production of red and white cells and platelets). He has participated in investigator-initiated trials [IIT] exploring the anti-inflammatory effect of commonly used serotonin-reuptake inhibitors in the treatment of low-risk myelodysplastic syndrome [MDS]. Additionally, he was co-investigator in several multi-institutional studies evaluating the use of monoclonal antibodies that reactivate the immune system (cells that fight leukemia) to target acute myelogenous leukemia (AML) and MDS. He also has a special interest in understanding the “origin of leukemia” [How cells acquire genomic/DNA changes modifications]. He is lead of the MyeloHub Acute Leukemia Multi-Institutional Consortium, a collaborative effort that seeks to integrate large genomic AML (and other hemopoietic myeloid malignancies) data into prevention, trial design and investigation of ethnic disparity outcome, among others.

Dr. Rivero’s philosophy of care
“Medical oncology is a unique area of medicine in which the relationship between the patient and their medical team forms a critical part of their journey. Developing continuity of care with each patient and their support network, while getting to know the person behind the diagnosis, is one of the most fulfilling aspects of my clinical work.”  – Dr. Rivero

About MedStar Georgetown Cancer Institute
MedStar Georgetown is part of the MedStar Georgetown Cancer Institute, which combines medical expertise, the latest therapies, and research across MedStar Health. Our research engine, the Georgetown Lombardi Comprehensive Cancer Center, is the only National Cancer Institute (NCI)-designated comprehensive cancer center in the Washington, D.C., region. We are privileged to offer patients progressive, state-of-the-art evaluation, research, and therapies for all forms of cancer.

Clinical areas of focus

  • Biological Targeted Therapy
  • Bone Marrow Aspiration
  • Bone Marrow Biopsy
  • Cancer
  • Cancer Chemotherapy
  • Cancer Immunotherapy
  • Chronic Lymphocytic Leukemia
  • Clinical Trials
  • Hairy Cell Leukemia
  • Intrathecal Chemotherapy
  • Leukemia
  • Lumbar Puncture
  • Precision Medicine
  • Side Effects Of Cancer Treatment
Show More

Conditions and procedures

Conditions I treat

  • Acute Lymphoblastic Leukemia (ALL)
  • Acute Myelogenous Leukemia (AML)
  • Aplastic Anemia
  • Cancer
  • Chronic Lymphocytic Leukemia
  • Chronic Myelocytic Leukemia
  • Chronic Myelomonocytic Leukemia
  • Hairy Cell Leukemia
  • Hematologic Malignancies
  • High Eosinophil Count
  • Leukemia
  • Lymphoma
  • Mastocytosis
  • Multiple Myeloma
  • Myelodysplastic Syndrome
  • Myeloproliferative Diseases
  • Side Effects Of Cancer Treatment
Show All Show Less

Procedures I perform

  • Biological Targeted Therapy
  • Bone Marrow Aspiration
  • Bone Marrow Biopsy
  • Cancer Chemotherapy
  • Cancer Immunotherapy
  • Clinical Trials
  • Intrathecal Chemotherapy
  • Leukemia Genomics
  • Lumbar Puncture
  • Precision Medicine
Show All button Press enter to expand Show Less

Practice locations

Distance from Change LocationEnter your Location

1650 Orleans Street
Room CRB1-204
Washington, DC, 20011

Get Directions

miles away

3800 Reservoir Road Northwest
Washington, DC, 20007

Get Directions

miles away



Fellowship Program: National Institutes of Health Clinical Center (2011)

Residency Program: John H. Stroger Jr. Hospital of Cook County (2005)

Medical School: Francisco de Miranda University (1994)


  • Recipient Early Career Faculty Award for Excellence in Patient Care.
  • Center of Excellence- Health Equity- Center of Excellence Research
  • Norton Rose Fulbright Faculty Excellence Award. (Teaching and Education)
  • Norton Rose Fulbright Faculty Excellence Award. (Development of educational material)
  • Top Hematologist and Oncologist 2021-Top doctors (Houston
  • Top Hematologist and Oncologist 2022 - Top doctors (Houston)
  • American Society of Hematology 2022 abstract award.

News and publications

  • Jang A, Rivero G. Inferior Survival Among Polycythemia Patients Exhibiting Body Mass Index Reduction. SN Comprehensive Clinical Medicine (Springer) accepted.
  • Tavares S, Dongarvar D, Mims M, Rivero G, Yellapragada S. Disparities in Mortality among Acute Myeloid Leukemia Related Hospitalizations. Cancer Medicine. 2022; 00:1-8. 3. 
  • Khan S, Tavares S, Apostolidou E, Rivero G, Yellapragada S. Luspartecept in Low-Risk Myelodysplastic Syndrome: A Real-World Single Institution Case Series. 2022; 1-4.
  • Advances and Future Goals in Acute Myelogenous Leukemia Therapy. Brittar G, De-Olivera Gomes D, Rivero G. Oncology & Hematology Review- 2022; 18(2). 
  • Prazwal A, Rivero G, Mims M, Haque M. Myeloid Sarcoma of the Skull Base: Case Report and Systematic Literature Review. Surgical Neurology International. 2022 (13); 202:1-10.
  • Bhakta P, Hamza M, Mehravaran S,  He Q, Tyring S,  Rady P, Rivero G, Cohen D, Sosa R. The contribution of human papilloma virus infection to cutaneous cell carcinoma in patients with chronic lymphocytic leukemia. EJHaem. 2021; 1-8. 
  • Chen Y, Talukder R, Merritt B, King K, Kimmel M, Rivero G, Sosa R. Genomic trajectory in leukemogenesis of myeloproliferative neoplasm: a case report. BMC Genomics. 2021. 14:137
  • Sun, Yuanyue; Blieden, Clifford, Rivero, G. Hemophagocytic lymphohistiocytosis and myelodysplastic syndrome. Journal of Medical Case Report.  2021;15 (98).
  • Fillmore N, Yellapragada S, Samur M, Rivero G, Pyarajan S, Do Nhan, Brophy M, Munshi N With Equal Access and Utilization of Resources, Younger African American Patients Have Superior Survival Compared to Caucasian Patients Diagnosed with Multiple Myeloma at the Veterans Affairs Hospitals. Blood. 2019; 19 (133): 2615-18.
  • Snijder J, Mihyawi N, Frolov A, Rivero G. Spontaneous remission in diffuse large cell lymphoma, an unusual phenomenon? Journal of Medical Case Report. 2019; 13:28.
  • Alcedo P, Hamad H, Rivero G (2017). Cytogenetic, epigenetic, immunological and   Infectious diseases basis for dysplastic hematopoeisis. Oncology & Hematology Review-13 (2) 81-91.
  • Soleja M, Mims M, Rivero G. Uncovering molecular abnormalities leading to the Warburg effect in primary refractory diffuse large B-cell lymphoma. Blood Cancer Journal. (104) 1-3; 2016.
  • Armas A, Chen C, Mims M, Rivero G. Uncovering clinical features of low-risk Philadelphia positive myelodysplasia. - Case Report in Hematology- 2017 Article ID 5404131. 
  • Kirtan N, Rivero G. Red Cell Transfusion and Progressive Growth Factor Independence Is Feasible with Adjuvant Sertraline in Low-Risk Myelodysplastic Syndrome (LR-MDS). Leukemia Research Report (1-3) 2015
  • Molina M, Rivero G. Pulmonary Complications of Azanucleoside Therapy in Patients with Myelodysplastic syndrome and Acute Myelogenous Leukemia. Case Report in Hematology. 5 (1-5) 2015
  • Li A, Yellapragada S, Mims M, Rivero G. Significant improvement in survival among patients diagnosed with low-risk myelodysplastic syndrome (MDS) treated with Selective Serotonin Reuptake Inhibitors (SSRIs). British Journal of Haematology. April 7, 2016.